Distinguished in Temporal Arteritis

Dr. William F. Rigby

Rheumatology
Mary Hitchcock Memorial Hospital
1 Medical Ctr Dr, 
Lebanon, NH 
Distinguished in Temporal Arteritis
Mary Hitchcock Memorial Hospital
1 Medical Ctr Dr, 
Lebanon, NH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Rigby is a Rheumatologist in Lebanon, New Hampshire. Dr. Rigby is rated as a Distinguished provider by MediFind in the treatment of Temporal Arteritis. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in NH
Hospital Affiliations
Mary Hitchcock Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

MARY HITCHCOCK MEMORIAL HOSPITAL
1 Medical Ctr Dr, Lebanon, NH 03756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
View 5 Less Clinical Trials

58 Total Publications

Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.
Journal: RMD open
Published: September 26, 2024
Similar Doctors
Distinguished in Temporal Arteritis
Dr. Hoke H. Shirley
Rheumatology
Distinguished in Temporal Arteritis
Dr. Hoke H. Shirley
Rheumatology

Concord Hospital Inc

246 Pleasant St, Suite 210, 
Concord, NH 
 (48.5 miles away)
603-789-9101
Experience:
43+ years
Languages Spoken:
English
See accepted insurances

Hoke Shirley is a Rheumatologist in Concord, New Hampshire. Dr. Shirley has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Temporal Arteritis. His top areas of expertise are Ankylosing Vertebral Hyperostosis with Tylosis, Behcet Disease, Temporal Arteritis, and Diffuse Idiopathic Skeletal Hyperostosis.

Distinguished in Temporal Arteritis
Dr. Todd F. Dombrowski
Rheumatology
Distinguished in Temporal Arteritis
Dr. Todd F. Dombrowski
Rheumatology

Dartmouth-Hitchcock Clinic

590 Court St, 
Keene, NH 
 (50.2 miles away)
603-354-5400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Todd Dombrowski is a Rheumatologist in Keene, New Hampshire. Dr. Dombrowski is rated as a Distinguished provider by MediFind in the treatment of Temporal Arteritis. His top areas of expertise are Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, Rheumatoid Arthritis (RA), and Temporal Arteritis. Dr. Dombrowski is currently accepting new patients.

Distinguished in Temporal Arteritis
Dr. Stephanie D. Mathew
Rheumatology
Distinguished in Temporal Arteritis
Dr. Stephanie D. Mathew
Rheumatology
1 Medical Center Dr, 
Lebanon, NH 
 (0.2 miles away)
603-650-8622
Languages Spoken:
English
See accepted insurances

Stephanie Mathew is a Rheumatologist in Lebanon, New Hampshire. Dr. Mathew is rated as an Advanced provider by MediFind in the treatment of Temporal Arteritis. Her top areas of expertise are Temporal Arteritis, Juvenile Temporal Arteritis, Giant Cell Arteritis (GCA), and Necrotizing Vasculitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rigby's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile